Guest col­umn: The 3 big waves re­shap­ing in­vest­ment strate­gies in ear­ly-stage biotech

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

We are at a time in life sci­ences when sig­nif­i­cant strides are be­ing made to solve some of the most com­plex med­ical chal­lenges. Rapid ad­vance­ments in sci­ence and tech­nol­o­gy cou­pled with abun­dant cap­i­tal are lead­ing to new in­vest­ment strate­gies that may per­ma­nent­ly change how com­pa­nies at the cut­ting edge of drug de­vel­op­ment are fund­ed.

Let’s take a step back. For years, ear­ly-stage in­vestors and drug de­vel­op­ment com­pa­nies faced im­pos­si­bly high fundrais­ing hur­dles, ham­pered by the high cost of cap­i­tal, low clin­i­cal suc­cess rates and a long reg­u­la­to­ry process that might stretch years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER